Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, et al
However, the introduction of semaglutide tablets and the development of higher-dose oral Read More GLP1s and Liver Disease: Rethinking MASLD Care Beyond Obesity and A1C Jan 26, 2026 Articles, Diabetes, Featured, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 2,667 views Nonalcoholic steatohepatitis (NASH) and metabolic dysfunctionassociated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide
4 MFP By the Numbers: The IPAY 2026 and IPAY 2027 cohorts include 25 total products produced by 16 manufacturers
PLoS Genet 15(1):32 Wang W, Arakawa H, Wang L et al (2017) Motor-coordinative and cognitive dysfunction caused by mutant TDP-43 could be reversed by inhibiting its mitochondrial localization